edotecarinum
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2003 (NCT00067314)
Timeline
Indications
Mechanism of action
- DNA topoisomerase IINHIBITOR
TOP1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1c2c(c3c4ccc(O)cc4n([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c3[nH]c4cc(O)ccc4c23)C(=O)N1NC(CO)CO- Mol. weight
- 608.56 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL435191 ↗
Also known as
- 12-beta-d-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-5h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6h)-dione
- 6-n-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy-13-glucopyranosyl-5h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6h)dione
- ed-749
- ed-749
- edotecarin
- edotecarin
- edotecarin
- edotecarin
- edotecarin
- edotecarina
- edotecarina
- edotecarinum
- edotecarinum
- j107088
- j 107088
- j-107088
- pf-804950
- pf-804950
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00087503 | Phase 2 | Apr 1, 2004 | Pfizer |
| NCT00068952 | Phase 3 | Aug 1, 2003 | Pfizer |
| NCT00072332 | Phase 1 | Aug 1, 2003 | Cornell University, National Cancer Institute (NCI) |
| NCT00067314 | Phase 2 | Jun 1, 2003 | Pfizer |
| NCT00070031 | Phase 2 | Jun 1, 2003 | Cornell University, National Cancer Institute (NCI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 2 | 2003 |
| Cornell University | Academic/Hospital | 2 | 2 | 2 | 2003 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2003 |
3 organizations
Page 1 / 1